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Abstract
Replicating viruses have broad applications in biomedicine, notably in cancer virotherapy and in the design of attenuated
vaccines; however, uncontrolled virus replication in vulnerable tissues can give pathology and often restricts the use of
potent strains. Increased knowledge of tissue-selective microRNA expression now affords the possibility of engineering
replicating viruses that are attenuated at the RNA level in sites of potential pathology, but retain wild-type replication
activity at sites not expressing the relevant microRNA. To assess the usefulness of this approach for the DNA virus
adenovirus, we have engineered a hepatocyte-safe wild-type adenovirus 5 (Ad5), which normally mediates significant
toxicity and is potentially lethal in mice. To do this, we have included binding sites for hepatocyte-selective microRNA mir-
122 within the 39 UTR of the E1A transcription cassette. Imaging versions of these viruses, produced by fusing E1A with
luciferase, showed that inclusion of mir-122 binding sites caused up to 80-fold decreased hepatic expression of E1A
following intravenous delivery to mice. Animals administered a ten-times lethal dose of wild-type Ad5 (5610
10 viral
particles/mouse) showed substantial hepatic genome replication and extensive liver pathology, while inclusion of 4
microRNA binding sites decreased replication 50-fold and virtually abrogated liver toxicity. This modified wild-type virus
retained full activity within cancer cells and provided a potent, liver-safe oncolytic virus. In addition to providing many
potent new viruses for cancer virotherapy, microRNA control of virus replication should provide a new strategy for
designing safe attenuated vaccines applied across a broad range of viral diseases.
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Introduction
Viruses have a highly successful history as prophylactic vaccines
and are also being developed for their intrinsic anticancer activities
[1]. In both settings the ability to undergo restricted replication is
highly desirable. Attenuated (but not killed) viral strains often
represent the most effective viral vaccines, affording the possibility
of persistent low level infection without significant pathology [2,3].
Unfortunately many viruses are not suitable for production of
attenuated forms, and reversion to wild-type represents a
significant risk. Equally the field of cancer ‘virotherapy’ relies on
selective replication of lytic viruses within cancer cells, leading to
cell death and spread of infection to adjacent cancer cells. Several
‘conditionally-replicating’ viruses have been engineered for
activation by tumour-associated changes, showing greater potency
in cancer cells than in normal cells. Unfortunately these agents are
generally attenuated compared to the equivalent wild-type virus
even in cancer tissues, and have so far shown little therapeutic
activity in clinical trials [4,5]. For both vaccination and cancer
virotherapy it would be attractive to produce viruses that show
wild-type replication activity at therapeutic sites (eg. within
tumours or at sites of antigen presentation) but are specifically
attenuated at sites of potential pathology.
The network of naturally-occurring non-coding microRNA
molecules [6] negatively regulates cellular gene expression post-
transcriptionally through a number of mechanisms that all involve
binding of microRNA to complementary regions within a
messenger RNA (mRNA) [7,8] leading to decreased protein
production [9]. Tissue-selective microRNA expression is now well
characterised [10], and it provides an opportunity to regulate
transgene expression from therapeutic nucleic acids and viruses.
This principle was originally developed by Brown et al. [11], who
showed that inclusion of microRNA mir-142-3p binding sites within
39UTR of retrovirally-encoded transgenes prevented expression in
antigen presenting cells, preventing stimulation of an immune
response and allowing long term transgene expression in other cells
without rejection. The diversity of tissue-specific microRNAs now
identified should enable this approach of selective attenuation of
viral expression to be developed in several different contexts [12].
It is also possible to use the microRNA system to regulate
replication of vaccines or conditionally-replicating ‘oncolytic’
viruses. The small size of the required insertion (microRNA
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flexibility in the design of capacity-restricted therapeutic viruses.
Equally the negative regulatory principle of using microRNA
regulation to inhibit viral replication in sites of toxicity, could allow
significant therapeutic potency by avoiding attenuation in target
sites. This approach has previously been used to generate
microRNA-controlled conditionally-replicating RNA viruses, in-
cluding Polio virus for vaccination and coxsackie virus for cancer
virotherapy. These viruses were engineered to contain binding
sites for neural and muscle specific microRNAs respectively. The
neural-restricted polio virus showed good vaccine potential, while
the muscle-restricted coxsackie virus showed decreased myositis
and improved anticancer efficacy [13,14].
In this study we have explored the use of this approach in
engineering a microRNA-controlled wild-type adenovirus, a DNA
virus, by expressing binding sites for microRNA mir-122 within
the 39 UTR of E1A. Mir-122 is highly and selectively expressed in
hepatocytes [10,15], and this modification might prevent expres-
sion of E1A within hepatocytes, thereby reducing adenovirus
replication and hepatotoxicity whilst maintaining its therapeutic
replication within tumour cells.
Results
Evaluation of potency of mir122 regulation in vitro
To assess the repression capabilities of mir-122, CMV
promoter-driven luciferase plasmids containing 0, 4 and 8 sense
or 4 anti-sense microRNA binding sites (representative structures
shown in Figure 1) were transfected into HEK-293, OVCAR-3
and HUH7 cell lines using DOTAP (Roche) and luciferase activity
was measured by luminometry after 24 h. The presence of the
microRNA binding sites had no effect on luciferase levels detected
in the mir-122 negative cell lines HEK-293 and OVCAR-3
(Figure 2). In contrast, in mir-122-positive HUH7 cells, lumines-
cence was decreased from 7.9610
5 RLU/mg (anti-sense control
plasmid) to 9.9610
4 RLU/mg (4 microRNA binding sites,
P=0.001)) and 3.4610
4 RLU/mg (8 microRNA binding sites,
P=0.001). The inclusion of 4 anti-sense microRNA binding sites
did not effect luciferase activity compared to the unmodified
control plasmid in any cell type. Whilst the inclusion of 8
microRNA binding sites did show improved repression in
comparison to 4 binding sites, we decided to use 4 binding sites
for future use in view of the repetitive nature of the insertion and
to minimise the likelihood of viral recombination.
Evaluation of potency of mir-122 regulation in vivo
Luciferase expression from the microRNA-controlled plasmids
shown in Figure 1 was assessed in murine livers in vivo, using an
Ivis100 imaging system. Plasmid vectors were delivered at
equimolar amounts by hydrodynamic delivery and imaging was
performed at 8, 24 and 48 h post injection. Control CMV
promoter-driven plasmids gave high levels of transgene expression
after 8 h (2.7610
11 RLU) while inclusion of 4 microRNA binding
sites in the same plasmid decreased expression to 5.7610
9 RLU, a
47-fold decrease in expression (Figure 3A). Total levels of
luciferase expression fell substantially over the next 40 h, although
the differential expression increased up to 129-fold (P=0.0064)
after 48 h (Figure 3C).
Plasmids containing the E1A promoter and E1A coding
sequence were engineered to generate an E1A-luciferase fusion
transcription cassette. This vector was then further modified to
contain four binding sites to mir-122 to allow in vivo imaging of
E1A expression (Figure 1). Following hydrodynamic delivery of
equimolar amounts of both vectors, expression from the plasmid
Author Summary
Attenuated viruses have found important applications in
medicine, including their use as vaccines (notably for
measles, mumps, polio, influenza, and chicken pox) and
their experimental development as selective cancer-killing
agents, so-called ‘‘virotherapy.’’ Wild-type versions are
often most effective in both of these settings; however,
attenuated viruses have usually been developed to
decrease the risk of significant viral pathology. Recent
advances in understanding regulation of gene expression
by microRNA now afford the possibility to design viruses
that are ‘‘selectively attenuated’’ in sites of potential
pathology, by engineering them for inhibition by micro-
RNA molecules that are expressed there. Here we have
engineered wild-type adenovirus for recognition by a
microRNA expressed in hepatocytes, producing a virus
that retains wild-type infection and replication at sites of
therapeutic activity (such as cancer cells) but is severely
attenuated in hepatocytes, both in vitro and in vivo. This
virus caused no significant liver toxicity to mice even when
applied at ten times the lethal dose of wild-type virus. The
ability to produce replication-competent viruses with key
toxicities removed should provide a new platform for
development of improved cancer treatments and better
vaccines for a broad range of viral diseases.
Figure 1. Plasmid construction. pCIK-Lux (referred to as pCMV-Luc) was cleaved with Not1 and concatamers of mir-122 binding sites (4 or 8 sense,
or 4 antisense; the sequence of the 4 sense insert is shown at the top of the figure) inserted into the luciferase 39UTR. Both pCMV-Luc and the version
containing 4 microRNA sites (pCMV-Luc-mir) were modified with the C terminal half of E1A expression cassette, isolated from pAd5WT (Ad5 wild-
type) by PCR. Both resulting constructs were then cloned into pAd5Kpn1, which contains the E1A promoter and coding sequence, to produce E1A
promoter regulated E1A-luciferase fusion constructs termed pE1A-Luc and pE1A-Luc-mir.
doi:10.1371/journal.ppat.1000440.g001
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sites) was much lower than from the equivalent pCMV vector,
probably reflecting relatively weak activity of the E1A promoter in
murine cells, however the inclusion of four microRNA sites within
this plasmid again mediated a significant decrease in expression
(86-fold after 8 h, P=0.01, Figure 3B). It was noticeable that
luciferase expression from the fusion protein decreased more
rapidly with time than from the pCMV-driven vectors, perhaps
reflecting the ability of E1A to negatively regulate its own
promoter (Figure 3C).
Mir-122 binding sites do not affect adenovirus activity in
mir-122–negative cells in vitro and in vivo
Adenoviruses containing E1A-luciferase fusion constructs on a
background of wild-type Ad5 (Figure 4(iii) and 4(iv)) were used to
infect mir-122-negative A549 and OVCAR-3 cell lines in vitro.
Luciferase activity from both Ad-E1A-Luc (containing no mir-122
binding sites) and Ad-E1A-Luc-mir122 (containing 4 mir122
binding sites) increased slowly between 8 and 24 h and then
showed a more rapid rise that was sustained up to at least 72 h
(Figure 4B and 4C). This profile of luminescence may reflect initial
transcription from the input viral genomes that increases rapidly
following viral genomic replication. The microRNA insertion into
the 39 UTR did not affect the profile of luciferase expression in
these cells, suggesting the modification did not influence the
stability of mRNA encoding the E1A-luciferase fusion protein, nor
did it inhibit virus replication in these mir-122-negative cells.
To ascertain whether the microRNA insertion would also be
inactive in mir-122- negative cells in vivo, viruses (1610
10 v.p.) were
injected subcutaneously in Balb/C mice (n=3) and animals were
imaged after 24 h. Results demonstrated no significant difference
between the expression from the two viruses (data not shown)
suggesting no effects of the microRNA at the subcutaneous site.
MicroRNA binding sites decrease activity of Ad-E1A-luc-
mir122 virus in mir122–positive cells in vitro and in vivo
Adenoviruses encoding the E1A-luciferase protein with and
without four microRNA binding sites were used to infect a
monolayer of the mir122 positive cell line Huh7. E1A-luciferase
expression was monitored by luminometry from 6 h to 72 h post-
infection (Figure 4E). Luciferase expression from the Ad5-E1A-
Luc showed a small but significant rise between 0 and 24 h
(reaching 1.1610
5 RLU/mg protein) and then increased rapidly,
rising to 1.7610
6 RLU/mg protein by 72 h. This suggests E1A
transcription and replication proceeded similarly to the situation in
A549 and OVCAR cell lines. In contrast, Ad5-E1A-Luc-mir122
virus showed significantly less luciferase expression at all time
points, reaching only 6.3610
4 RLU/mg after 72 h (P=0.0001 for
both 48 and 72 h). The differential in luciferase expression
between the viruses with and without microRNA binding sites
increased over time, suggesting decreased genome replication of
Ad5-E1A-Luc-mir122 compared to Ad5-E1A-Luc. In order to
confirm that this differential in luciferase expression was due to
mir-122 knockdown of E1A, a precursor RNA mimic of mir-122
(Ambion) was introduced into A549 cells to simulate hepatocyte
expression. Ad-E1A-Luc-mir122 and either the mir122 pre-cursor,
or negative control pre-mir (Ambion) were added to cells and
luciferase readings performed after 24 h. Results showed that the
introduction of the pre-mir122 reduced luciferase, and therefore
E1A, expression from 9.2610
4 RLU (negative control pre-mir) to
3.4610
3 RLU (P=0.0001, Figure 4B).
To assess the in vivo activity of these viruses and to observe the
effects of time on E1A expression over 96 h, 5610
10 vp of Ad5-
E1A-Luc and Ad5-E1A-Luc-mir122 were injected intravenously
into Balb/C mice. Animals were imaged at 6, 24, 48, 72 & 96 h
(Figure 5). After 6 h, Ad-E1A-Luc showed a luminescence signal of
1.6610
8 RLU whilst Ad-E1A-Luc-mir122 showed only 3.0610
6,a
differential of 52-fold. Interestingly, the signal from the Ad5-E1A-
Luc treated mice increased by 2.5610
9 RLU between 48 and 72 h
(Figure 5, time course) possibly reflecting a wave of virus
replication. At the same time the microRNA regulated virus
showed only a relatively small increase (a rise of 3.4610
7 RLU).
After 96 h the differential expression between the viruses with and
without microRNA sites had reached 80 fold.
MicroRNA regulation of wild-type Ad5 (Ad5WT) reduces
genomic replication and hepatic toxicity
In order to assess the effects on hepatic toxicity of including mir-
122 binding sites within wild-type adenovirus, 5610
10 v.p of
Ad5WT and Ad5-mir122 were injected intravenously to Balb/C
mice. One mouse in the study which received Ad5WT became
hunched and immobile, and was sacrificed after 60 h with visible
Figure 2. Effects of microRNA binding sites on expression of CMV promoter driven luciferase plasmids in vitro. Cells were seeded in
triplicate in 12 well plates. After 24 h 0.5 mg of plasmid DNA (containing 0 (black), 4 (light grey) or 8 (white) sense mir-122 binding sites, or 4 antisense
binding sites (dark grey)) was mixed with 2.5 ul DOTAP (Roche) reagent. 24 h following transfection cells were lysed and relative luminescence was
measured using 25 ml cell lysate. N=3, Error bars +/2standard deviation and data is shown as RLU/mg cell protein, determined by BCA assay. (**
P,0.005).
doi:10.1371/journal.ppat.1000440.g002
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anaesthesia 72 h post-injection and blood was allowed to clot.
Serum from both groups was tested for Alanine Aminotransferase
(ALT) levels and Aspartate Aminotransferase (AST) to assess
hepatic damage. Mice administered wild-type Ad5 showed
significantly increased ALT levels (90 times higher than control
mice treated with PBS, P=0.0001; Figure 6A) suggesting
substantial liver damage had occurred. Mice administered Ad5-
mir122 showed approximately 15-fold less serum ALT (5 times
normal) demonstrating that less liver toxicity had occurred with
this virus. AST readings demonstrated similar results with a 17
fold decrease in AST in serum from mice administered Ad5-
mir122 compared to serum from mice receiving Ad5WT
(P=0.0002, Figure 6A). To evaluate viral replication and tissue
Figure 4. Regulation of E1A expression. (A) Structures of viruses engineered and used in this study. (i) Ad5-WT (ii) Four tandem repeats of
binding sites for mir-122 were inserted into the 39 UTR of E1A. (iii) Luciferase coding sequence was inserted into Ad5 to generate a fusion with the
E1A coding sequence. (iv) Four tandem repeats of binding sites for mir-122 were inserted into 39 UTR of luciferase in the virus shown in iii. (B) A549
cells were seeded at 5610
4 cells per well and transfected with pre-mir122 (Ambion) or pre-mir negative control (Ambion). Immediately following
transfection Ad-E1A-Luc-mir122 was added at 10 vp/cell in 450 ml DMEM media (10% FCS). 18 h later, 30 pmol/well of pre-cursor mir122 and
negative control precursor microRNAs were added to each well in addition to the 500 ml described above. Luciferase readings were performed at
24 h (p=,0.0005). (C–E) Time course of luciferase expression of Ad5-E1A-Luc (solid squares) and Ad5-E1A-Luc-mir (open squares) in mir-122-
negative OVCAR3 (C) and A549 (D) cells, and in mir-122-positive Huh7 cells (E) in vitro. (*** P,0.0005).
doi:10.1371/journal.ppat.1000440.g004
Figure 3. Effects of including binding sites for microRNA122a on expression of plasmids in vivo following hydrodynamic delivery
to mice. (A) Imaging luminescence (8 h from mice administered pCMV-Luc not containing (left panel) and containing (right panel) four binding sites
for mir-122 (plasmids pCMV-Luc and pCMV-Luc-mir in Figure 1).The animal on the right side of all images is a control treated with PBS, but mock
injected with luciferin, used to provide a background reading. (B) Imaging luminescence (8 h from mice administered pE1A-Luc fusion constructs not
containing (left panel) and containing (right panel) four binding sites for microRNA122a (plasmids pE1A-Luc and pE1A-luc-mir in Figure 1). The animal
on the right is an untreated control. The two images in A are directly comparable with each other, as also the two images in B; however scaling is
different between (A) and (B) in order to accommodate substantially different signal intensities from these plasmids. (C) Time course of luciferase
expression from CMV promoter-driven and E1A promoter driven constructs shown in A and B. Black=8 h, Grey=24 h, White=48 h. n=4 throughout
(except pCMV-Luc-mir122 where n=3), error bars show standard deviation.
doi:10.1371/journal.ppat.1000440.g003
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Livers taken from mice administered wild-type Ad5 showed an
average of 2610
9 genomes/mg liver (wet weight; Figure 6B). In
the total liver this represents approximately 60-fold more genome
copies compared to the total amount of virus originally injected,
suggesting significant genome replication. In contrast, livers from
mice administered Ad5-mir122 showed only 8610
7 virus ge-
nomes/mg liver, representing less than a doubling compared to
the input dose (P=0.0001 for Ad5-mir122 compared to Ad5WT).
These data confirm that the microRNA suppression of E1A is
capable of significantly reducing replication of the virus genome in
murine liver in vivo.
Histological analysis showed a dramatic difference between
animals administered wild-type Ad5 and those administered Ad5-
mir122. Wild-type Ad5 induced vacuolation, haemorrhaging and
abnormal nuclear morphology, while livers from mice adminis-
tered Ad5-mir122 showed very little pathology, with some mice
showing no aberrant morphology in any liver section (Figure 6C).
Histological images of liver from a mouse administered 5610
10 vp
of a non-replicating adenoviral vector are presented for compar-
ison, showing similar or slightly greater liver pathology than was
induced by Ad5-mir122.
The maximum tolerated dose of Ad5WT given i.v. is reported as
about 1610
9 PFU [16], and this was confirmed in studies using
nude mice bearing HepG2 human hepatocellular carcinoma
xenografts (data not shown). Animals were found to tolerate higher
levels of Ad-mir122 (6610
10 v.p., 9610
9 PFU) with only mild
weightloss,althoughwhenthisdoseofAd-mir122wasadministered
ontwoconsecutivedays,all mice wereshowing signsofvirus-related
toxicity by day 4 following the first injection. These mice were put
down and the livers demonstrated macroscopic signs of viral liver
damage. It therefore appears that, in tumour bearing animals, the
maximum tolerated dose of Ad-Mir122 lies between 6610
10 and
1.2e10
11v.p/mouse (9610
9–1.8610
10 pfu).
Discussion
Molecular engineering of replicating viruses to avoid pathology
whilst maintaining potency in therapeutic sites would provide an
important new platform for design of viral vaccines and oncolytic
Figure 5. Luciferase transgene expression following intravenous administration of reporter viruses to mice in vivo. Groups of four
mice were administered intravenously 5610
10 virus particles of Ad5-E1A-Luc (left hand group of each pair of images) or Ad5-E1A-Luc-mir122 (right
hand group of each pair) and luminescence was quantified using an Ivis100 imaging system after 6 h–96 h. The mouse on the right of all images is an
untreated control, mock injected with luciferin for background levels. Images within pairs can be directly compared, although the scaling is different
between time points (see scale bars for details). The graph summarises the expression profile as a function of time.
doi:10.1371/journal.ppat.1000440.g005
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this using a DNA virus, wild-type Ad5, engineered to avoid its
major toxicity in murine liver by including four binding sites for
hepatocyte-specific mir-122 within the 39UTR of E1A.
To measure E1A expression non-invasively we introduced a
luciferase coding region 39 to the E1A coding region of wild-type
virus in order to produce a contiguous E1A-luciferase expression
cassette, where E1A splicing would produce a series of E1A-
luciferase fusion proteins. This novel virus (including a modified
version containing 4 mir-122 binding sites in the E1A 39 UTR)
produced strong luciferase activity in vitro and in vivo that reported
E1A protein levels clearly, enabling non-invasive real-time
assessment of protein translation including the effects of virus
genome replication. Measuring E1A protein in this way is a more
reliable indicator of microRNA activity than measuring E1A
mRNA, since microRNA regulation is known to affect protein
translation via multiple pathways. However, given that our
microRNA target sites are precisely complementary to mir-122
it is likely that argonaut 2 -mediated RNA cleavage is responsible
for the majority of the knockdown observed. While the presence of
the luciferase sequence slightly decreased the rate of cell killing in
vitro, compared to the corresponding virus without luciferase, a
complete cytopathic effect was still achieved in permissive cells
after one extra day. This suggests that the fusion proteins retain all
essential E1A functions. This is perhaps unsurprising given that
E1A protein has been shown to still operate despite significant
deletions and insertions, lacking both enzyme activity and
significant secondary structure [17].
Wild-type Ad5 is normally capable of an abortive genome
replication cycle in murine liver in vivo, where it mediates
considerable and sometimes lethal hepatotoxicity [16,18]. It was
unclear whether microRNA regulation could successfully control
Ad5, since the DNA genome is not a direct target for microRNA
recognition and it is known that even small amounts of E1A
translation can lead to genomic replication, which will then
provide a template for more transcription providing a greater
challenge for microRNA control. Nevertheless, although E1A
production in mir-122-positive Huh7 cells in vitro was decreased
only about 95% following introduction of 4 mir-122-binding into
the E1A-luciferase reporter virus, in vivo luciferase imaging
suggested a greater suppression of E1A expression by mir-122,
showing a 50-fold differential after 6 h that rose to 80-fold after
96 h. This may reflect a higher expression of mir-122 in murine
hepatocytes in vivo than in human Huh7 cells. To complement the
E1A reporter luciferase data, hepatic replication and toxicity was
also assessed using wild-type Ad5 and compared with a ‘wild-type’
modified to contain four mir-122 sites (Ad-mir122). After 72 h the
serum ALT was decreased 15-fold for the microRNA-containing
version compared to wild-type, hepatic morphology showed far
less evidence of toxicity (most sections appearing normal) and the
number of viral genomes found in liver was decreased by a factor
of 25. These findings are consistent with those using the E1A-
Figure 6. Assessment of hepatotoxicity of wild-type Ad5 modified with microRNA binding sites. (A) Measurement of serum ALT (black
bars) and AST (grey bars) 72 h following intravenous administration of 5610
10 viral particles of wild-type Ad5 and Ad5-mir122. Analysis was
performed as described in the Methods section. (B) Adenovirus genomes in murine liver were measured by real time PCR 72 h following intravenous
administration of 5610
10 viral particles of wild-type Ad5 WT and Ad5-mir122, as described in the Methods section. (C) Assessment of liver histology.
The left liver lobe from each mouse was immersed in 10% buffered formalin overnight at room temperature, embedded in wax and sectioned using a
vibratome. Sections were stained with haematoxylin and eosin and analysed by light microscopy at640 magnification. Mice were treated with PBS,
non-replicating E1, E3-deleted Ad5 expressing GFP (Ad5-GFP), wild-type Ad5, or wild-type Ad5 modified to contain 4 mir-122 binding sites, as
indicated. (*** P,0.0005).
doi:10.1371/journal.ppat.1000440.g006
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122-binding sites had a dramatic effect on hepatic activity and
toxicity of the virus. It is worth noting that in this study the viruses
were applied at dose in vivo (5610
10 vp/mouse), well above the
lethal dose for wild-type Ad5 [16], hence this regulatory strategy
appears capable of controlling the activity of significant quantities
of virus. Also of note is the ability of mir-122 in mouse liver to
tightly regulate the very high levels of E1A-luciferase fusion
protein achieved following hydrodynamic plasmid delivery
(Figure 3), some 10-fold higher than those shown by the viruses.
This suggests that the doses of virus used in this study do not even
come close to exceeding the regulatory capacity of mir-122. When
even higher virus doses were applied, the maximum tolerated dose
of Ad5-mir122 was estimated at between 6610
10 and
1.2e10
11v.p/mouse (9610
9–1.8610
10 pfu), and such doses pre-
sumably allow the virus to break through regulation by hepatic
mir-122. Nevertheless these doses are high, affording a range of
doses where the virus may be applied therapeutically.
A similar approach, using three microRNA binding sites, has
recently been evaluated for regulating activity of CR2-deleted
adenovirus in vitro [19]. However, the authors concluded that
further attenuation was required in order to prevent CPE in Huh7
cells. The superior performance of the virus reported here may
reflect the presence of four microRNA binding sites (rather than
three) in the 39 UTR although it is also possible that Huh7 cells
have insufficient mir-122 to achieve the level of virus control seen
in primary hepatocytes.
MicroRNA-based virus regulation strategies should find a
variety of applications in biotechnology. Their small size (an
individual site is typically 22 bp) allows insertion of multiple
binding sites, recognising diverse microRNAs, without compro-
mising virus packaging efficiencies. In addition the small insertion
size and typical proximity to essential virus genes and regulatory
regions (e.g the E1A poly A signal) decreases the likelihood of
propagating deletions. Hence a range of stable and versatile agents
may be produced using this approach.
Tissue-selective abrogation of virus replication to prevent
unwanted pathology should find important applications in cancer
virotherapy and also in the production of a new generation of
attenuated vaccines for viral diseases. For example, introduction of
binding sites for mir122 into the Hepatitis A, B or Hepatitis E
genome should prevent replication in hepatocytes and abrogate
the main viral toxicity, whilst maintaining infection and possible
replication at other cellular sites. Such an approach could yield an
important new range of therapeutic vaccines, with applications
across the broad sphere of viral diseases.
Materials and Methods
Ethics statement
All animal experimentation was performed in accordance with
the terms of UK Home Office guidelines and the UKCCCR
Guidelines for the Welfare of Animals in Experimental Neoplasia.
Engineering of microRNA–regulated luciferase reporter
plasmids
Luciferasereporter plasmids sensitive to mir-122 were prepared by
introducingconcatamersofbindingsitesformir-122(4or8senseor4
antisense binding sites) into the 39UTR of the luciferase transcription
cassette. A CMV-driven luciferase-expressing plasmid vector pCIK-
Lux (a kind gift from Dr Deborah Gill) was cleaved with NotI,
oligonucleotides were annealed at 95uC, cooled and ligated into
dephosphorylated vector. This produced vectors pCMV-Luc-mir
(shown in Figure 1), pCMV-Luc-mir122X8 and pCMV-Luc-
mir122anti, together with the control (hereafter referred to as
pCMV-Luc) which contained no mir-122 binding sites.
The coding region for the C terminal half of E1A was PCR
amplified using Accuprime PFX (Invitrogen) and primers (forward
ATT ATA AGA TCT GGA TAG CTG TGA CTC CGG TCC
TTC, reverse TAT TCC ATG GAT GGC CTG GGG CGT
TTAC) using a plasmid containing wild-type Ad5 as template. These
primers introduced unique BglII and Nco1 restriction sites to the 59
and 39 termini respectively. The purified PCR product was cleaved
with BglII and Nco1 and cloned into pCMV-Luc and pCMV-Luc-
mir described above, using the same enzymes, producing a fusion
between the C terminal half of E1A and luciferase, including zero or
four microRNA sites in the 39 UTR. These products were subcloned
using PshA1 and Hpa1 into a plasmid pAd5-Kpn1 (produced by
restriction of wild-type Ad5, see below) to produce plasmids (pE1A-
Luc and pE1ALuc-mir122) in which E1A was C-terminally fused to
the luciferase coding sequence. The overall scheme of plasmid
cloning is shown in Figure 1.
Cloning of microRNA–regulated wild-type Ad5
Wild-type Ad5 plasmid containing kanamycin resistance (a kind
gift from Dr Reuben Hernandez) was cleaved with BstZ17I and
recircularised by blunt ended ligation. This vector (Ad5-BstZ17I)
was then further cleaved and re-ligated using Kpn1 to increase the
number of unique restriction sites available for further cloning. This
vector is referred to as Ad5-Kpn1. The 4 microRNA binding sites
for mir122 were PCR amplified from pCMV-Luc-mir (described
above) to introduce Dra1 sites to each end. The purified PCR
product was cleaved with Dra1 and blunt end ligated into Ad5-
Kpn1 which was cleaved with Hpa1 in the E1A 39 UTR. Insertion
of microRNA binding sites downstream of E1A was confirmed by
DNA sequencing. Ad5-Kpn1-mir122 was reconstituted to Ad5-
BstZ17I using the Kpn1 gel-extracted fragment from Ad5-BstZ17I.
To generate full size adenovirus genome Ad5-BstZ17I-mir122 was
cleaved with BstZ17I, dephosphorylated and subject to homologous
recombination with full size wild-type Ad5 ampicillin resistant
vector (a kind gift from Dr Peter Searle) and selected on kanamycin.
Insertion of microRNA binding sites was confirmed by sequence
analysis. Restriction digestion of the resulting vector confirmed full
size adenovirus had been recovered.
Cloning of microRNA–regulated luciferase reporter based
on wild-type Ad5
pE1A-Luc-mir and pE1A-Luc (which are modified forms of
Ad5-Kpn1 described above) were reconstituted to Ad5-BstZ17I
using the Kpn1 gel-extracted fragments from Ad5-BstZ17I. To
generate full size adenovirus genome Ad5-BstZ17I-E1ALuc-
mir122 and Ad5-BstZ17I-E1ALuc were cleaved with BstZ17I,
dephosphorylated and subject to homologous recombination with
full size wild-type Ad5 vector (a kind gift from Dr Peter Searle) and
selected on kanamycin. Insertion of microRNA binding sites and
luciferase was confirmed by sequence analysis. Restriction digests
of the resulting vectors confirmed full size adenoviruses had been
recovered. Genomic structures and sizes of the viruses are shown
in Figure 4A.
Adenovirus preparations
All adenoviruses were grown in A549 cells, purified by double
banding in CsCl gradients with benzonase treatment after the first
banding. Viral particle (vp) number was determined by measuring
DNA content using a modified version of the PicoGreen assay
(Invitrogen, Paisley, UK) [20]. TCID50 calculated with the
KA ¨RBER statistical method [21] was used to estimate the
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plaque forming units/ml (pfu/ml). Adenovirus preparations
characteristics are as follows: Ad5 wild-type: 1.13610
12 vp/ml,
1.98610
11 pfu/ml and particle:infectivity (P:I) ratio of 5.6; Ad5-
mir122: 1.29610
12 vp/ml, 2.01610
11 pfu/ml and particle:infec-
tivity (P:I) ratio of 6.4. All virus preparations were screened for
endotoxin and verified negative prior to use.
Maintenance of cell lines
Human hepatocellular carcinoma HUH7 cells, A549 lung
carcinoma cells, OVCAR3 ovarian cancer cells and HEK293
human embryonic kidney cells were obtained from the European
Collection of Cell Cultures (Porton Down, UK), and maintained
in DMEM with 10% foetal bovine serum (FBS) (PAA Laborato-
ries, Yeovil, UK) including penicillin (25 U/ml) and streptomycin
(10 mg/ml).
Luciferase expression assays in vitro
Cells were seeded in triplicate in 12 well plates. After 24 h
plasmid DNA (0.5 mg) was added to 50 ml of HBS buffer and
mixed with 2.5 ml DOTAP reagent (Roche) also in 50 ml sterile
HBS. The complex was incubated at room temperature for
30 min. 100 ml of transfection mixture was added to each well and
incubated at 37uC for 4 h. Cells were washed with PBS and
incubated with DMEM containing 2% FBS. 24 h following
transfection media were removed and 150 ml reporter cell lysis
buffer (Promega) was added to the cells. Cells were then frozen at
280uC for .1 h before thawing. Luciferin (25 ml) (Promega,
Southampton, UK) was added to 25 ml aliquots of cell lysate and
relative luminescence was measured by luminometry (Lumat LB
9507, Berthold Technologies, Redbourn, UK).
Pre-mir 122 transfection
A549 cells were seeded at 5610
4 cells per well and incubated
overnight. Pre-mir122 (Ambion) and pre-mir negative control
(Ambion) were re-suspended to 50 mM and then further diluted 10
fold. 3 ml perwell of this dilution ofeachpre-mir wasadded to 22 ml
Opti-MEM medium (Invitrogen). 2 ml per well of NeoFx transfec-
tionreagent (Ambion) was added to 23 ml Opti-MEM solution. Pre-
mir/Opti-MEM was mixed with the NeoFx/Optimem and allowed
to complex for 10 minutes. A549 cells were washed with PBS and
the transfection mixture added to cells at a total volume of 50 ml.
Total amount of pre-mir is 15 pmol/well. Immediately following
transfection Ad-E1A-Luc-mir122 was added at 10 vp/cell in 450 ml
DMEM media (10% FCS). 18 h later, 30 pmol/well of pre-cursor
mir122 and negative control pre-cursor microRNAs were added to
each well in addition to the 500 ml described above. Luciferase
readings were performed at 24 h.
Real time (quantitative) PCR (Q–PCR) for Ad5
The Q-PCR methodology for measurement of adenoviral
particles has been previously described [22]. Viral DNA from
infected cell or tissue samples were extracted using a mammalian
genomic DNA miniprep kit (Sigma). Reactions were performed
using Applied Biosystems master mix following the manufacturer’s
protocol. The cycles were as follows: 94uC 10 min; 40 times (94uC
30 s, 60uC 1 min). Primers sequences for targeting Ad5 fiber are:
FW- TGG CTG TTA AAG GCA GTT TGG (Ad5 32350–
32370 nt) and RV- GCA CTC CAT TTT CGT CAA ATC TT
(Ad5 32433–32411 nt) and the TaqMan probe- TCC AAT ATC
TGG AAC AGT TCA AAG TGC TCA TCT (Ad5 32372–
32404 nt), dual labeled at the 59 end with 6-carboxyfluorescein
and the 39 end with 6-carboxytetramethylrhodamine. The results
were analyzed with the Sequence Detection System software
(Applied Biosystems). Standard curves for tissues and cells were
prepared by spiking samples of cell lysate or tissue homogenate
with serial dilutions of known concentrations of virus particles and
then extracting and analysing each sample separately by Q-PCR
as described above.
Measurement of Serum Alanine Aminotransferase (ALT)
and Aspartate Aminotransferase (AST)
Blood was taken from mice by cardiac puncture and allowed to
clot (15 min, room temperature) and spun at 1200 g for 10 min.
Serum was isolated and immediately frozen at 220uC). Samples of
thawed serum (5 ml) were added to ALT reagent (995 ml, Micro-
genics) or AST reagent (995 ml, Microgenics) in a 1 ml quartz
cuvette, incubated at 37uC and the change in absorbance (340 nm)
per minute was monitored. Units of ALT and AST activity were
calculated according to the manufacturer’s instructions.
Assessment of hepatic expression of plasmids in mice
Plasmids were administered by hydrodynamic injection
(0.8 pmole/mouse, using a 10% body volume of PBS administered
over 5–10 s with a 27 gauge needle) into the tail veins of Balb/c
mice. Non-invasive measurement of luminescence was performed
after 8, 24 and 48 h using an IVIS 100 system (Xenogen, MA)
under isofluorane anaesthetic. Luciferin was administered by
intraperitoneal injection (15.8 mg/ml in PBS, 100 ml/mouse)
4 min prior to imaging. Flux levels were analyzed with Living
Image Software (Xenogen, MA).
Evaluation of the activity of adenoviruses containing
microRNA binding sites in vivo
Clodronate was a gift of Roche Diagnostics GmbH, Mannheim,
Germany. It was encapsulated in liposomes as described previously
[23]. Viruses were administered intravenously (unless otherwise
indicated) and all animals were pretreated with bisphosphonate
liposomes (100 ml/mouse, obtained from Dr Nico van Rouijen)
24 h before. For imaging expression of E1A encoded within
replication-competent Ad5, E1A-luciferase reporter viruses with
and without 4 binding sites for mir122 (Ad5-E1A-luc and Ad5-
E1A-luc-mir122) were injected intravenously to Balb/c mice
(5610
10 v.p./mouse). Animals were imaged after 6, 24, 48, 72 and
96 h as described above.
To study the ability of mir-122-binding sites included within
wild-type A5 to decrease hepatic replication of virus genomes and
tissue damage, 5610
10 v.p./mouse of Ad5WT and Ad5-mir122
were injected i.v. Animals were monitored twice daily and
sacrificed after 72 h for measurement of genome replication (by
QPCR) and assessment of pathology (by histological analysis).
Histology
The left liver lobe from each mouse was immersed in 10%
buffered formalin overnight at room temperature, embedded in
wax and sectioned using a vibratome. Sections were stained with
haematoxylin and eosin and analysed by light microscopy at 640
magnification.
Statistical analysis
In vitro data are expressed as the mean of 3 replicates 6standard
deviation unless otherwise stated. In vivo data are expressed as the
mean of four replicates 6standard deviation, except using the
plasmid pCMV-Luc-Mir for which n=3. Significance was
evaluated using t-test and denoted on the graphs as * P,0.05,
** P,0.005, *** P,0.0005.
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